JP2025500784A5 - - Google Patents

Info

Publication number
JP2025500784A5
JP2025500784A5 JP2024534144A JP2024534144A JP2025500784A5 JP 2025500784 A5 JP2025500784 A5 JP 2025500784A5 JP 2024534144 A JP2024534144 A JP 2024534144A JP 2024534144 A JP2024534144 A JP 2024534144A JP 2025500784 A5 JP2025500784 A5 JP 2025500784A5
Authority
JP
Japan
Application number
JP2024534144A
Other languages
Japanese (ja)
Other versions
JPWO2023105479A5 (https=
JP2025500784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/061991 external-priority patent/WO2023105479A1/en
Publication of JP2025500784A publication Critical patent/JP2025500784A/ja
Publication of JPWO2023105479A5 publication Critical patent/JPWO2023105479A5/ja
Publication of JP2025500784A5 publication Critical patent/JP2025500784A5/ja
Pending legal-status Critical Current

Links

JP2024534144A 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用 Pending JP2025500784A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163287557P 2021-12-09 2021-12-09
US63/287,557 2021-12-09
US202163290765P 2021-12-17 2021-12-17
US63/290,765 2021-12-17
PCT/IB2022/061991 WO2023105479A1 (en) 2021-12-09 2022-12-09 Use of amivantamab to treat colorectal cancer

Publications (3)

Publication Number Publication Date
JP2025500784A JP2025500784A (ja) 2025-01-15
JPWO2023105479A5 JPWO2023105479A5 (https=) 2025-12-12
JP2025500784A5 true JP2025500784A5 (https=) 2025-12-12

Family

ID=84537874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534144A Pending JP2025500784A (ja) 2021-12-09 2022-12-09 結腸直腸癌を治療するためのアミバンタマブの使用

Country Status (9)

Country Link
US (2) US20230183360A1 (https=)
EP (1) EP4444426A1 (https=)
JP (1) JP2025500784A (https=)
KR (1) KR20240112963A (https=)
AU (1) AU2022407875A1 (https=)
CA (1) CA3241933A1 (https=)
IL (1) IL313410A (https=)
MX (1) MX2024007066A (https=)
WO (1) WO2023105479A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547867A (zh) * 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2026022733A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer
WO2026022739A1 (en) * 2024-07-23 2026-01-29 Janssen Biotech, Inc. Combination therapies for the treatment of colorectal cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
SG11202108311RA (en) * 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
PH12022552076A1 (en) * 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS

Similar Documents

Publication Publication Date Title
JP2025500784A5 (https=)
BR102022025291A2 (https=)
CL2026000082A1 (es) Método y disposición para predecir cod en un proceso de tratamiento de aguas residuales.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13170U (https=)
BY13164U (https=)
BY13135U (https=)
BY13174U (https=)
BY13176U (https=)
BY13172U (https=)
BY23963C1 (https=)
BY13155U (https=)
BY13169U (https=)